Pfizer Reports Promising Midstage Data for Monthly Weight-Loss Injection
Advancing the Weekly Injection Paradigm Pfizer announced on Monday that its experimental once-monthly GLP-1 weight-loss injection, danuglipron, demonstrated a side-effect profile comparable to current market leaders like Novo Nordisk’s Wegovy during its latest midstage clinical trial. The pharmaceutical giant is positioning the drug, also known as berobenatide, as a potential game-changer in the obesity treatment…